Abstract
The effects of MK-801 at doses from 0.005 to 1 mg/kg IP on linguopharyngeal events (protrusions, retrusions and swallows) were determined in rats to find out whether MK-801 resembles ketamine in its capacity to increase the frequency of recurrence of such events that we have demonstrated in previous studies. All rats receiving a dose of 0.05 mg/kg or higher showed an increase in linguopharyngeal event frequency within 5 min and this enhancement (3-fold from baseline level) was maintained for longer than 1 h. At the lowest dose of 5 µg/kg the effect lasted only very briefly. A general increase in motor behavior was also observed within 10 min of drug administration. More complex patterns of motor behavior, consisting of stereotypical head bobbing, paw movements reminiscent of walking activity, nystagmus, and ataxia were observed with doses of 0.25 mg/kg and higher. All rats showed a marked startle response at early stages post-injection and hypersensitivity to external stimuli such as noise or movement in the room. However, there was an absolute lack of coordinated avoidance responses normally associated with such startle responses or arousing stimuli.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aldes LD, Prater SR, Chronister RB, Marco LA (1988) Ketamine as a pharmacological model for tongue dyskinesia. Biol Psychiatry 23:159–168
Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mamalian neurons by N-methyl-aspartate. Br J Pharmacol 79:565–575
Aram J, Church J, Davies SN, Lodge D, Martin D (1986) Comparison of phencyclidine, thienylcyclohexylpiperidine and MK-801 an NMDA antagonists on rat spinal and cortical neurones. Br J Pharmacol [Proc Suppl] 89: 778P
Bleuler E (1950) Dementia precox or the group of schizophrenias (Trans. Zukin J) International University Press, New York
Clineschmidt BV, Martin GE, Bunting PR (1982a) Anticonvulsant activity of (+)-5-methyl-10, 11-dihydro-5H-dibenzo[a,d] cyclohepten-5, 10-imine (MK-801), a substance with potent anti-convulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:123–134
Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982b) Central sympathominetic activity of (+)-5-methyl-10, 11 dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:135–145
Clineschmidt BV, Williams M, Witoslawski JJ, Bunting PR, Risley EA, Totaro JA (1982c) Restoration of shock-suppressed behavior by treatment with (+)-5methyl-10, 11-dihydro-5H-dibenzo [a,d]cyclohepten-5, 10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:147–163
Corssen G, Domino EF (1966) Dissocciative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 45:29–40
Foster AC, Gill R, Iversen LL, Woodruff GN (1987) Systemic administration of MK-801 protects against ischaemia-induced hippocampal neurodegeneration in the gerbil. Br J Pharmacol [Proc Suppl] 90:9P
Gerhardt SC, Bernard P, Pastor G, Boast CA (1986) Effects of systemic administration of the NMDA antagonist, CPP, on ischemic brain damage in gerbils. Soc Neurosci Abstr 12:59
Harrison NL, Simmonds MA (1985) Quantitative studies on some antagonists of N-methyl-D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 84:381–391
Kemp JA, Priestley T, Woodruff GN (1986) MK-801, a novel, orally active anticonvulsant, is a potent, non-competitive N-methyl-D-aspartate receptor antagonist. Br J Pharmacol [Proc Suppl] 89:535P
Kemp JA, Foster AC, Wong EHF (1987) Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 10:294–298
Koek W, Kleen E, Mudar PJ, Woods JH (1986a) Phencyclidine-like catalepsy induced by the excitatory amino acid antagonist DL-2-amino-5-phosphonovalerate. Behav Brain Res 19:257–259
Koek W, Woods JH, Ornstein P (1986b) Phencyclidine-like behavioral effects in pigeons induced by sylstemic administration of the excitatory amino acid, antagonist, 2-amino-5-phosphonovalerate. Life Sci 39:973–978
Koek W, Woods JH, Ornstein P (1987) A simple and rapid method for assessing similarities among directly observable behavioral effects of drugs: PCP-like effects of 2-amino-5-phosphonovalerate in rats. Psychopharmacology 91:297–304
Kraeplin E (1919) Signs of mental disorder. Alienist and Neurologist 40:85
Labruyere J, Fuller TA, Olney JW, Price MT, Zorumski C, Clifford D (1986) Phencyclidine and ketamine protect against kainic acid-induced seizures and seizure-related brain damage. Soc Neurosci Abstr 12:344
Lodge D, Anis NA (1982) Effects of phencyclidine on exitatory amino acid activation of spinal interneurons in the cats. Eur J Pharmacol 77:203–204
Maragos WF, Chu DCM, Greenamyre JT, Penny JB, Young AB (1986)3H-TCP binding and NMDA receptors. Eur J Pharmacol 123:173–174
Maragos WF, Penney JB, Young AB (1988) Anatomic correlation of NMDA and3H-TCP-labeled receptors in rat brain. Neurosci 8:493–501
Marco LA, Reed TF, Aldes LD, Chronister RB (1988) An electrographic characterization of ketamine-induced linguopharyngeal motor activity. Clin Neuropharmacol 11:141–150
Marco LA, Pendleton R, Reed TF, Bringham TE, Chronister RB, Aldes LD (1989) Ketamine-induced tongue protrusions in rats. Comp Biochem Physiol 94C:29–33
Martin D, Lodge D (1985) Ketamine acts as a non-competitive N-methyl-D-aspartate antagonist on frog spinal cord in vitro. Neuropharmaccology 24:999–10003
O'Donohue TL, Pest CB, French E, Pert A, DiMaggio DA, Everist H, Quirion R (1983) Evidence of an endogenous CNS Ligand for the PCP receptor. In: Hruby DJ, Rich DH (eds) Proceedings of the Eighth American Peptide Symposium. Pierce Chemical Company, Rockford IL, pp 433–436
Olney JW, Price JT, Fuller TA, Labruere J, Samson L, Carpenter M, Mahan K (1986) The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics. Neurosci Lett 68:29–34
Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencycildine and related drugs. Science 244:1360–1362
Quirion R, DiMaggio DA, Frendh FD, Contreras PC, Shiloach J, Pert CB, Everist II, Pert A, O'Donohue T (1984) Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides 5:967–973
Piercey MF, Hoffmann WE, Kaczkofsky P (1988) Functional evidence for PCP-like effects of the anti-stroke candidate MK-801. Psychopharmacology 96:561–562
Reimherr FW, Wood DR, Wender PH (1986) The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol Bull 22:237–242
Simon RP, Swan JH, Griffiths T, Meldrum BS (1984) Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226:850–852
Snyder SH (1980) Phencyclidine. Nature 285:355–356
Wieloch T (1985) Hypoglycemia-induced neuronal damage prevented by an N-methyl-D-aspartate antagonist. Science 230:681–683
Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83:7104–7108
Woznisk DF, Olney JW, Kettinger L III, Price M, Miller JP (1990) Behavioral effects of MK-801 in the rat. Psychopharmaccology 101:47–56
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marco, L.A., Joshi, R.S. & Chronister, R.B. Effects of MK-801, a non-competitive NMDA antagonist, on linguopharyngeal events in rats. Psychopharmacology 103, 462–466 (1991). https://doi.org/10.1007/BF02244245
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244245